跳至主要内容
临床试验/EUCTR2005-002095-15-IT
EUCTR2005-002095-15-IT进行中(未招募)不适用

The effect of sulodexide in overt type 2 diabetic nephropathy. - Overt

KERYX BIOPHARMACEUTICALS INC.0 个研究点目标入组 2,240 人开始时间: 2006年3月20日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
2,240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • The population for this study includes women and men with type 2 diabetes and clinically overt proteinuria protein creatinine ratio PCR the geometric mean of 3 AM first voided urine of 61619;900 mg/G 101.7 mg/mmol for women and 61619;650 mg/G 73.45 mg/mmol for men . In addition, serum creatinine in women must be between 1.3 and 3.0 mg/dL 115 265 956;mol/L , inclusive, and in men between 1.5 and 3.0 mg/dL 133-265 956;mol/L , inclusive. If the serum creatinine falls outside the specified creatinine criteria, a patient may enter the Run-in Period only if the glomerular filtration rate GFR is between 25 and 61472;45 mL/min, as calculated by the Modification of Diet in Renal Disease MDRD formula.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Type I diabetes, known non-diabetic renal disease, renal allograft, need for a combination of ACEI and ARB, cardiovascular disease, need for chronic immunosuppressive treatement, cancer, HIV, evidence of hepatic disfunction, untreated urinary tract infection.

研究者

相似试验

The effect of sulodexide in overt type 2 diabetic... | 临床试验